This study is looking at a new treatment called **axicabtagene ciloleucel** for people with a type of cancer called large B-cell lymphoma (LBCL). LBCL is a cancer of the white blood cells, which are part of the immune system. The study wants to see if this drug works better than the usual treatments. If you take part in this study, you'll be watched for up to 15 years to see how you do.
To join, you need to have LBCL confirmed by tests and be at high risk as shown by a score system called IPI. You should have only had one cycle of a treatment that includes a drug called rituximab. Your body needs to be in good health overall. Some types of LBCL and other health problems might not allow you to participate.
- Length: The study includes a follow-up phase for up to 15 years.
- Visits: You will need to do regular follow-up visits.
- Risks: There may be risks from the treatment and long-term follow-up.
How understandable was the trial content above?
Hard to understand
Easy to understand